Kornimate/medical-research-clean huggingface dataset:
effect of lens presentation on the clinical oculomotor assessment at near

Conditions: Vision Disorders

Summary: this study will compare near clinical oculomotor parameters (heterophoria, vergence ranges, ac/a and accommodative findings) measured when lenses and/or prisms are introduced using three different instruments namely: (i) a standard manual phoropter, (ii) an electronic phoropter and (iii) a wearable adaptive refractor (visionfit).

previous studies have demonstrated differences in a number of near oculomotor parameters \[e.g., heterophoria, accommodative convergence to accommodation (ac/a) ratio\] when measured in a manual phoropter versus a trial frame. these differences may be due to variations in proximal vergence, differences in head and eye position and restriction of the peripheral visual field. further, a number of standard clinical oculomotor procedures require the use of risley rotary prisms. while prism is typically introduced in a smooth, ramp-like fashion with manual phoropters, step changes in prism are created with electronic phoropters. the precise effect of these variations on clinical measurements is unclear. accordingly, after a routine refractive examination, a standard clinical near assessment (comprising near heterophoria, ac/a ratio, horizontal vergence ranges, amplitude of accommodation and negative and positive relative accommodation) will be carried out on the same individuals through: (i) a standard manual phoropter (american optical model 11625), (ii) an electronic phoropter (topcon cv-5000) and (iii) a wearable adaptive refractor (visionfit). the latter resembles a trial frame mounted on a helmet carrier (similar to a binocular indirect ophthalmoscope headset) but includes adaptive lenses that can be changed electronically.

Eligibility criteria:
inclusion criteria: * corrected visual acuity of at least 20/20 (logmar = 0.0) or better in each eye exclusion criteria: * strabismus, amblyopia, manifest ocular disease.
transform-hf: torsemide comparison with furosemide formanagement of heart failure

Conditions: Heart Failure

Summary: transform-hf is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. approximately 6,000 patients with heart failure will be enrolled. the primary objective of the transform-hf study is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over 12 months in patients with heart failure who are hospitalized.

* this study will be a randomized, unblinded, two-arm, multi-center clinical trial of patients with heart failure who are hospitalized. heart failure need not be the reason for hospitalization. patients will be randomized 1:1 to either oral torsemide or oral furosemide prior to hospital discharge. oral dosing of torsemide compared to furosemide will be 1mg:2mg. the specific loop diuretic dose will be at the discretion of the treating physician with the above noted conversion. * trial enrollment occurs before hospital discharge, at the discretion of the healthcare provider. * as appropriate, adherence to the randomized medication will be encouraged during the remainder of hospitalization and will continue post-discharge. patients will receive follow-up per standard care without any additional study-specific visits. * patients will have 30-day, 6-month and 12-month follow-up phone contacts for assessments of vital status, interval hospitalizations, adherence, and quality of life. "central follow-up" and collection of hospital discharge summaries via irb-approved mechanisms. subsets of patients enrolled early in the study have additional phone contacts beyond 12 months, up to 30 months, at six month intervals, to document vital status.

Eligibility criteria:
inclusion criteria: 1. patient hospitalized (≥ 24 hours or over a change in calendar date) with worsening of chronic heart failure, or new diagnosis of heart failure and meets one of the following criteria: 1. has a left ventricular ejection fraction (ef) ≤40% within 24 months prior to and including index hospitalization by any method (with most recent value used to determine eligibility) 2. has an elevated natriuretic peptide level (either nt-pro-b-type natriuretic peptide or b-type natriuretic peptide) during index hospitalization as measured by local laboratory (with most recent value used to determine eligibility) 2. plan for a daily outpatient oral loop diuretic regimen upon hospital discharge with anticipated need for long-term loop diuretic use 3. ≥ 18 years of age 4. signed informed consent exclusion criteria: 1. end-stage renal disease requiring renal replacement therapy 2. inability or unwillingness to comply with the study requirements 3. history of heart transplant or actively listed for heart transplant 4. implanted left ventricular assist device or implant anticipated \<3 months 5. pregnant or nursing women 6. malignancy or other non-cardiac condition limiting life expectancy to \<12 months 7. known hypersensitivity to furosemide, torsemide, or related agents

Keywords: loop diuretic
home-based conservative care model for advanced kidney disease

Conditions: Chronic Kidney Diseases

Summary: this is a randomized pilot study to test the feasibility and acceptability of a novel conservative care (cc) pathway among patients with advanced chronic kidney disease (ckd) who have chosen to forgo initiation of maintenance dialysis, their caregivers and providers.

this study is a randomized pilot study to test the acceptability and feasibility of a cc pathway, called the kidney care at home program, with patients with advanced ckd who have chosen to forgo dialysis, their caregivers and providers. the novel cc program will be developed upon an existing home-based multidisciplinary care (mdc) program in the veterans affairs (va) called the home-based primary care (hbpc) program. hbpc provides for veterans with multimorbidity and functional limitation with the goal of supporting veterans' quality of life and mitigating the complications of illness through to the end of life. the investigators hypothesize that hbpc serves as the ideal starting ground to build the va's first cc program for veterans with advanced ckd. the investigators will use implementation science and ethnographic research methods, including field observations, interviews, medical record review, and serial structured surveys on quality of life, symptom burden, care satisfaction and goal concordant care to assess the feasibility and acceptability of the kidney care at home program (intervention) vs. usual care (control).

Eligibility criteria:
inclusion criteria: patients: * receives primary +/- nephrology care from vaps as defined as having at least 1 outpatient primary or nephrology visit in the prior year * advanced ckd as defined as defined as having 2 or more outpatient measures of an egfr 20 ml/min/1.73m2 separated by 90 or more days * unsure or do not wish to undergo maintenance dialysis * agreement by their va primary +/- nephrology care provider that patients can participate in the study caregivers: * nominated by enrolled patient as a caregiver whom patient agrees to participate in the study clinicians: * employed at vaps * identified by enrolled veterans as important to their ckd and nominated by the veteran to be interviewed for the study exclusion criteria: patients: * unable to complete "teach-back" method of informed consent * currently receiving maintenance dialysis * currently enrolled in hbpc program caregivers: * unable to complete "teach-back" method of informed consent * if a veteran withdraws from the study, their caregivers' participation in the study is also terminated at that time clinicians: * if a veteran withdraws from the study, their clinicians will no longer be eligible to participate in interviews

Keywords: ckd
planned vaginal delivery vs planned cesarean delivery in preterm twins

Conditions: Twin Pregnancy

Summary: the incidence of twin pregnancies has increased and currently accounts for 1.8% of all deliveries. 47.5% of twins are born prematurely (vs. 6% for singletons) of which 9.9% before 32sa. caesarean section rates are also higher than for singletons (53.7% vs 19.2%) and 31.8% of caesarean sections are performed before delivery. the optimal mode of delivery for preterm twins remains controversial. the latest recommendations for clinical practice emphasize that it is not appropriate to recommend one mode of delivery rather than another in the case of twin pregnancies at any term. in view of all these elements, we wished to carry out a retrospective study at the montpellier university hospital in order to compare the neonatal outcome of preterms twins according to their mode of delivery : planned vaginal delivery versus planned cesarean delivery.


Eligibility criteria:
inclusion criteria: * twins born at montpellier university hospital * between 24sa and 32sa+6 * january 2010 to july 2019 * the mothers must have gone into labour spontaneously or after preterm rupture of membranes * first twin in cephalic presentation exclusion criteria: * twin to twin transfusion syndrome * monoamniotic pregnancies * cause of delivery other than preterm labor or preterm rupture of membranes * lethal malformation * first twin in breech or transverse presentation

Keywords: mode of delivery prematurity survival at discharge survival without severe morbidity
curcumin's effect on diabetic patients with atherosclerotic cardiovascular risk

Conditions: Diabetes Mellitus, Type 2; Dyslipidemias; Hypertension

Summary: the aim of the study is to assess the safety and efficacy of curcumin supplementation in combination to the conventional therapy in improving the clinical outcomes, oxidative stress and inflammation in diabetic patients with risk of ascvd.

atherosclerotic cardiovascular disease (ascvd) is one of the most devastating consequences of diabetes mellitus (dm), especially when combined with other comorbid conditions such as dyslipidemia and hypertension. to lessen the probability of ascvd, modifying an individual's lifestyle and regulating one's lipid profile, blood pressure, and glucose levels are all beneficial approaches that decrease the risk of ascvd occurrence. numerous diseases, including hypertension, dyslipidemia, and diabetes mellitus, have been shown to be significantly influenced by both oxidative stress and inflammation. curcumin is thought to regulate blood pressure, lipid profile, blood glucose levels. moreover, it is claimed that curcumin can alleviate inflammation and oxidative stress. curcumin is therefore suggested to have a beneficial role in lowering the risk of atherosclerotic cardiovascular diseases.

Eligibility criteria:
inclusion criteria: 1. adult male or female patients aged 40 years or older 2. a calculated 10 year ascvd risk score of 5 % or more 3. patient previously or newly diagnosed with hypertension 4. patient previously or newly diagnosed with dyslipidaemia 5. patients diagnosed as type 2 diabetes mellitus taking insulin or oral hypoglycemic agent with controlled hba1c \< 10% 6. willingness and ability to give informed consent. exclusion criteria: 1. congenital or acquired bleeding disorders. 2. cholelithiasis, gall bladder or biliary tract disease or other active liver diseases. 3. pregnant or breastfeeding women. 4. oral hypoglycemic drugs that affect cardiovascular diseases risk. 5. patients with clinical ascvd (myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease).

Keywords: diabetes mellitus ascvd risk curcumin inflammation oxidative stress diabetes complication
a study of contralateral limb block

Conditions: Limb Pain, Phantom

Summary: this research is being done to determine if an anesthetic like lidocaine, may be effective when injected around the sciatic nerve of the intact limb in patients with limb loss pain on the contralateral side.


Eligibility criteria:
inclusion criteria: * lower extremity amputation performed more than 12 months before study enrollment * plp/rlp in affected amputated limb \> 4 on nrs26 * pain duration of more than 6 months despite a trial of conservative therapies for at least 2 months, including oral medications, topical medicines, physical therapy, and physical modalities (i.e., heat, cold, transcutaneous electrical nerve stimulation, phonophoresis) * willingness to undergo image guided diagnostic nerve block exclusion criteria: * refusal / inability to participate or provide consent * contraindications to diagnostic nerve block * non-neurogenic source of plp/rlp * current opioid use \> 50 morphine milligram equivalents per day * any interventional pain treatment in the residual limb within the last 30 days * severe uncontrolled medical condition (i.e., hypertensive crisis, decompensated hypothyroidism) * use of investigational pain drug within past 30 days or other concurrent clinical trial enrollment
a safety study of nivolumab in combination with ipilimumab in participants with advanced non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: a study to evaluate safety in participants with chemotherapy-naïve stage iv or recurrent non-small cell lung cancer treated with nivolumab in combination with ipilimumab

a study to evaluate safety in participants with chemotherapy-naïve stage iv or recurrent non-small cell lung cancer treated with nivolumab in combination with ipilimumab

Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * 1) stage iv or recurrent non-small cell lung cancer * 2) eastern cooperative oncology group (ecog) performance status of 0-1 * 3) prior adjuvant or neoadjuvant chemotherapy for local, advanced disease allowed if completed at least 6 months prior to randomization exclusion criteria: * 1) known epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma syndrome(alk) translocations that are sensitive to targeted inhibitor therapy * 2) active, known or suspected autoimmune disease or hiv infection * 3) prior treatment with any drug that targets t cell co-stimulation pathways (such as checkpoint inhibitors) * 4) untreated central nervous system metastases other protocol defined inclusion/exclusion criteria could apply
a study of avastin (bevacizumab) in combination with xelox or folfox-4 in patients with metastatic colorectal cancer.

Conditions: Colorectal Cancer

Summary: this 2 arm study will compare the pharmacokinetics and safety of avastin at steady state under 2 different dosing regimens, in combination with xelox (oxaliplatin + xeloda) or folfox-4 (oxaliplatin, leucovorin and 5-fluorouracil). patients randomized to the xelox arm will receive avastin (7.5mg/kg iv) on day 1 of each 3 week cycle; patients randomized to the folfox-4 arm will receive avastin (5mg/kg iv) on day 1 of each 2 week cycle. the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * adenocarcinoma of the colon or rectum, with metastatic or locally advanced disease; * \>=1 target lesion. exclusion criteria: * patients who have previously received systemic treatment for advanced or metastatic disease; * patients who have received adjuvant treatment for non-metastatic disease in past 3 months; * previous therapy with oxaliplatin or avastin.
ppi therapy impact on gerd after sleeve gastrectomy

Conditions: Gastro Esophageal Reflux; Barrett Esophagus; Bariatric Surgery Candidate

Summary: the trial would to try to establish: * the best post-operative ppi prescription protocol after sleeve gastrectomy * the impact of ppi therapy on postoperative peptic diseases (erosive gastropathies, ulcers, duodenitis, esophagitis and/or barrett) * the impact of ppi therapy on post-operative gerd symptoms (assessed with the use of two standard tests: mrge-hrql and gerdq

45 patients candidate to primary sg and randomized in 3 study groups (15 per group) group a: no treatment (control group) group b (standard dose-long term): lansoprazole buccal tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months group c (standard dose-short term): lansoprazole buccal tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months

Eligibility criteria:
inclusion criteria: * patients candidates for primary sg * patients adhering to the follow-up protocol * age between 18 and 65 years * no bmi limits exclusion criteria: * gastric and/or esophageal diseases (routine preoperative endoscopy) * patients candidate for revisional bariatric surgery * chronic preoperative ppi therapy * using of ppi treatment for postoperative complications * conversion to open surgery * patients allergic to ppi * patients undergoing concomitant surgery * patients with hiatal hernia undergoing concomitant cruroplasty

Keywords: reflux, ppi, sleeve gastrectomy
knowledge regarding diagnosis of mih among dental interns in faculty of dentistry cairo university

Conditions: Molar Incisor Hypomineralization

Summary: assessment of knowledge of dental interns regarding diagnosis of mih among group of interns in faculty of dentistry cairo university

the study will be done in faculty of dentistry cairo university in form of survey with data being gathered via a questionnaire. the survey was conducted among the dental interns

Eligibility criteria:
inclusion criteria: * any nationality both gender exclusion criteria: * interns who refuse to participate

Keywords: mih, knowledge , molar incisor hypomineralization
development and validation of a digital optotype for near vision in greek language.

Conditions: Presbyopia; Low Vision; Near Vision

Summary: primary objective of our study is to develop and validate a computer-based digital near-vision optotype based on the greek version of the print mnread.

present study aims to develop and validate a computer-based digital near-vision optotype based on the greek version of the print mnread. specifically, it aims to evaluate the level of agreement between the conventional printed greek mnread chart and the corresponding digital chart, as well as test-retest reliability of the digital optotype. to address these aims, four reading parameters measured with the print and the digital version are compared. these parameters are the following: 1. reading acuity (ra) 2. maximum reading speed (mrs) 3. critical print size (cps) 4. accessibility index (acc) all the comparisons take place in two groups: a) a normal vision group (nvg), and b) a low vision group (lvg) in order to estimate the reading capacity in a population with a wide range of vision.

Eligibility criteria:
inclusion criteria: * adequate literacy of written greek language exclusion criteria: * dyslexia * attention-deficiency * former diagnosis of mental diseases * former diagnosis of psychiatric diseases

Keywords: digital near vision chart critical print size reading acuity reading speed digital greek mnread
study evaluating ski-606 in subject with solid tumors

Conditions: Tumors

Summary: the purpose of this study is to evaluate the safety and tolerability of oral ski-606 (100, 200, 300 or 400 mg) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (mtd) in this subject population. this study will also obtain preliminary information on the pharmacokinetics and antitumor activity of orally administered ski-606 in subjects with advanced malignant solid tumors


Eligibility criteria:
inclusion criteria: 1. advanced or recurrent solid malignancy confirmed histologically or cytologically for which no effective therapy is available 2. recovery from acute adverse effects of prior therapies to £ grade 1 (excluding alopecia) 3. eastern cooperative oncology group (ecog) performance status of 0 - 1 4. adequate hepatic, renal, and bone marrow function 5. age 20 to 74 years 6. willingness of male and female subjects, who are not surgically sterile or postmenopausal, to use reliable methods of birth control for the duration of the study and for 6 months and 30 days after the last dose of test article for male and female, respectively 7. life expectancy of at least 12 weeks exclusion criteria: 1. use of any systemic antitumor agents or any investigational agent within 28 days before the enrollment (42 days if the previous chemotherapy included nitrosoureas or mitomycin c) 2. ongoing clinical requirement for administration of a strong inhibitor of cyp3a4 3. prior exposure to ski-606 or any other src-kinase inhibitor 4. major surgery or radiotherapy within 2 weeks before the enrollment (recovery from previous surgery should be complete before day 1) 5. subjects unable or unwilling to swallow ski-606 capsules 6. active central nervous system (cns) metastases, as indicated by clinical symptoms, cerebral edema, requirement for corticosteroids and/or progressive growth 7. recent or ongoing clinically-significant gastrointestinal disorder 8. pregnant or breastfeeding women 9. subjects who meet the following criteria: * evidence of serious active infection, significant medical or psychiatric illness * history of unexplained syncope or known ventricular arrythmia * known seropositivity to hiv, or current or chronic hepatitis b or hepatitis hepatitis c * hypokalemia * unstable concurrent medical conditions * any other condition that, in the investigator's judgment, make the subject inappropriate for this study the subject inappropriate for this study

Keywords: phase 1 ski-606 solid tumor
ultrasound guidance for embryo transfer

Conditions: Infertility

Summary: randomized controlled study comparing the tvus versus taus guidance during the procedure of embryo transfer.

the aim of this study was to compare between transvaginal and transabdominal ultrasound guided embryo transfer as regarding clinical pregnancy rate, patient comfort, time required for embryo transfer and endometrial visualization at time of embryo transfer.

Eligibility criteria:
inclusion criteria: all patients undergoing autologous icsi and frozen embryo transfer (fet) cycles. exclusion criteria: 1. cases of sever ovarian hyperstimulation requiring embryo cryopreservation 2. gestational surrogate cycles 3. oocyte donation cycles 4. very poor responders 5. patients with inadequate visualization of the uterus by ultrasound. 6. very difficult mock embryo transfer.

Keywords: embryo transfer icsi transvaginal ultrasound
lymphatic osteopathic manipulative medicine to enhance coronavirus (covid-19) vaccination efficacy

Conditions: COVID-19

Summary: the purpose of this project is to study the impact of osteopathic manipulative medicine (omm) treatments, such as lymphatic myofascial release and thoracic pump techniques severe acute respiratory syndrome-associated coronavirus 2 (sars-cov-2) antibody levels in patients who receive the mrna-1273 (moderna) covid-19 vaccine and to consider if these omm strategies allow a stronger more robust immune response.


Eligibility criteria:
inclusion criteria: * inclusion criteria will include age greater than 18 years old and having safely received the covid-19 vaccine. exclusion criteria: * exclusion criteria will include age under 18 years old, malignancy/cancer, ongoing infection, coagulopathy history, use of anticoagulant medications, and fracture or acute injury of the torso neck or upper extremities. lymphatic omm is safe during pregnancy and this does not need to be an exclusion criteria.

Keywords: covid-19 osteopathic manipulative medicine antibody